Neprilysin is an enzyme that contributes to the breakdown of the biologically active natriuretic peptides and several other vasoactive compounds. Inhibiting neprilysin has been a therapeutic target for several compounds that have been tested in cardiovascular disease, including ecadotril, candoxetril, omapatrilat and LCZ696. While ecadotril, candoxetril and omapatrilat were initially tested in hypertension and/or heart failure, lack of efficacy and side effects led to discontinuation of their development. LCZ696 (sacubitril-valsartan) is a first in class angiotensin receptor neprilysin inhibitor (ARNI) that has been developed for use in heart failure. This compound is comprised of two molecular moieties in a single crystalline complex -an angiotensin receptor blocker valsartan, and a neprilysin inhibitor pro-drug -and has now been tested in hypertension, in a phase II trial in heart failure with preserved ejection fraction (HFpEF), and has demonstrated greater efficacy than enalapril in a phase III trial in heart failure with reduced ejection fraction.
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4 glomerular filtration rate (GFR) resulting in natriuresis and diuresis, thus decreasing total body sodium and fluid. Finally, the NPs also reduce renin release from renal juxtaglomerular cells, thereby reducing plasma angiotensin II (and subsequent secretion of aldosterone), resulting in vasodilation. Because natriuretic peptides are released in the setting of fluid overload, measurement of NPs is a reliable diagnostic marker of dyspnea due to cardiac causes and of the severity of heart failure (5).
NPs are cleared in several ways; receptor mediated degradation and breakdown by extracellular proteases (6) . The NPRC receptor is thought to function primarily as a "clearing" receptor which can bind all three natriuretic peptides resulting in receptor-mediated internalization and degradation. Natriuretic peptides are also broken down by the neutral endopeptidase neprilysin, also known as membrane metallo-endopeptidase. Neprilysin is expressed in several tissues but most commonly in the kidney. It catalyzes the degradation of numerous endogenous peptides such as ANP, BNP, CNP, bradykinin, substance P, andrenomedullin, glucagon, vasoactive intestinal peptide, and also contributes to the breakdown of angiotensin II (1) . Other proteases such as insulin degrading enzyme may play a role in NP degradation as well, and lack of significant physiologic alterations in mice who lack neprilysin suggest that other degradation pathways may compensate when neprilysin is absent or inhibited (7) .
Therapeutic targeting of the NP system in Heart Failure
In heart failure, the natural rise in natriuretic peptides are ineffective at alleviating fluid overload. One treatment strategy that has been employed is exogenous administration of nesiritide, a synthetic BNP drug. In the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) trial, nesiritide improved dyspnea at 3 hours compared to placebo, and M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 reduced pulmonary capillary wedge pressure compared to nitroglycerin, in patients with acute heart failure (8) . Nesiritide was associated with significant hypotension, and a subsequent analysis raised concerns about its safety in heart failure (9) . Moreover, nesiritide must be delivered intravenously, is costly, and has not proven to reduce morbidity or mortality. In the largest trial to directly test the efficacy of nesiritide in acute heart failure, ASCEND, participants with acute heart failure were randomized to nesiritide or placebo plus usual care.(10) The coprimary endpoints were reductions in death or hospitalization for heart at 30 days or improvement in self-assessed dyspnea at 6 or 24 hours. Nesiritide did not reduce the rate of death or HF hospitalization at 30 days, but was associated with a non-significant improvement in dyspnea to a modest degree.
Neprilysin inhibition represents a potential alternative strategy to exogenous BNP administration by preventing the breakdown of endogenous natriuretic peptides. Candoxatril, the first neprilysin inhibitor available orally, was associated with a dose dependent increase in ANP and natriuresis, but also increased concentrations of angiotensin II because of the effect of neprilysin on the breakdown of angiotensin II (11) . Candoxatril was not shown to reduce BP in hypertensive individuals, failed to show reduction in systemic vascular or pulmonary resistance in heart failure patients, and its development was discontinued (12) . Another neprilysin inhibitor, ecadotril, was tested in a dose-ranging study in 279 heart failure with reduced ejection fraction patients in which safety and efficacy were assessed (13) . Patients were randomized to one of five doses of ecadotril or placebo. Plasma and urinary cGMP were increased in a dose-dependent manner, but there were no changes in plasma renin activity, angiotensin II levels, endothelin I, norepinephrine or NT-proBNP. There were numerically more deaths in the patients receiving ecadotril and no evidence of efficacy, so development of the compound was discontinued.
Omapatrilat was the first representative drug acting through a dual neprilysin-reninangiotensin system (RAS) inhibition mechanism. As an inhibitor of both neprilysin and the angiotensin converting enzyme (ACE), this drug proved more potent than candoxatril in lowering blood pressure and improving hemodynamics in patients with heart failure (14, 15) .
While these initial results with omapatrilat in both hypertension and heart failure were promising, an outcomes trial in heart failure failed to show substantial benefit in comparison with the ACE inhibitor enalapril (16) . Moreover, the high occurrence and greater severity of angioedema observed in several hypertension clinical studies resulted in withdrawal of the drug from its route to FDA approval. The increased risk of angioedema was thought to be due to an increased circulating concentration of bradykinin resulting from inhibition of three proteases -ACE, aminopeptidase and neprilysin -which all contribute to its degradation, with resulting increased vasodilation and vascular permeability.
The Angiotensin receptor neprilysin inhibitor LCZ696
LCZ696 (sacubitril-valsartan) is a first in class angiotensin receptor neprilysin inhibitor (ARNI). LCZ696 is a novel, dual-acting crystalline complex comprised of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan in their anionic forms, sodium cations and water molecules. Soon after oral ingestion, LCZ696 dissociates into sacubitril (a neprilysin inhibitor pro-drug AHU-377, which is enzymatically cleaved to the active form LBQ657) and valsartan (17) . LCZ696 was designed to have a reduced risk of angioedema owing to the fact that it only inhibits one of the enzymes responsible for bradykinin breakdown.
In a single dose pharmacokinetic study, valsartan and AHU377 were rapidly absorbed following LCZ696 administration with a maximum concentration achieved between 1.7-2. Half-lives of LBQ657 and valsartan are similar at 12 hours and 14 hours, respectively, allowing for twice daily administration.
In a multi-dose study, similar to the single dose study, peak plasma concentrations were rapidly reached for LCZ696, sacubitril, and LBQ657, which indicates rapid breakdown and The dose normalized bioavailability of the valsartan component of LCZ696 is 40%-60% higher than would be delivered by the equimolar amount of valsartan as an individual drug. This increased bioavailability may be due in part to the fact that valsartan in LCZ is present in its anionic form, whereas is normally in the form of a free acid. In a bioavailability study, the mean plasma concentration time curves of valsartan 320mg and LCZ696 400 mg were very similar, meeting criteria for drug bioequivalence for systemic exposure of valsartan. There are limited data regarding metabolic pathways for sacubitril and LBQ657 and their alteration of metabolism of drugs which are substrates for the CYP450 system.
CLINICAL TRIALS OF LCZ696
There have been relatively few clinical trials of LCZ696, although these include trials in hypertension, heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). 
LCZ in Heart Failure with Preserved Ejection Fraction (HFpEF)
Heart failure with preserved ejection fraction (HFpEF) accounts for up to 50% of patients with HFpEF (21) . Despite the fact that patients hospitalized with HFpEF have similar overall mortality as patients with HFrEF, no specific therapies have proven benefit in HFpEF. The ability of the angiotensin receptor neprilysin inhibitor to simultaneously inhibit the reninangiotensin aldosterone axis and augment endogenous natriuretic peptides provided the rationale for testing this therapy in heart failure across the spectrum of ejection fraction. The PARAMOUNT trial assessed the efficacy LCZ696 in patients with heart failure preserved ejection fraction (22) . Inclusion in this trial required patients to have an ejection fraction equal to or greater than 45%, signs and symptoms of heart failure, and elevation of NT-proBNP. Patients were randomized to LCZ696 200 mg b.i.d. or valsartan 160 mg b.i.d., which is the bioequivalent amount of valsartan in that dose of LCZ696. The primary endpoint of the trial was change in NTproBNP level from baseline to 12 weeks. NT-proBNP is not a substrate for neprilysin and thus remains an accurate measure of the severity of heart failure even in the setting of neprilysin inhibition. Patients were followed through 36 weeks for additional endpoints.
By 4 weeks, NT-proBNP level was reduced in the LCZ 696 arm, and was significantly reduced by 26% compared with valsartan at 12 weeks, meeting the primary endpoint. In addition, at 36 weeks, patients in the LCZ arm had greater improvement in left atrial size and greater improvement in NYHA class. These findings were similar in all pre-specified subgroups.
NT-proBNP reduction was sustained in the LCZ arm through 36 weeks, though by 36 weeks, NT-proBNP had declined in the valsartan arm so that levels were no longer significantly different. Blood pressure was lowered to a greater extent in the LCZ696 arm. Nevertheless, subsequent analyses have shown that the effect on reduction in NT-proBNP, improvement in LA M A N U S C R I P T
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10 size and NYHA class were independent of the blood pressure lowering effect (23) . Moreover, despite the substantial reduction in blood pressure in the LCZ696 arm, eGFR was not reduced in patients receiving LCZ696 and was significantly higher than in those receiving valsartan.
LCZ696 was well tolerated in these patients, with no significant differences in adverse events between groups.
These hypothesis generating findings have provided the rationale for a large outcomes trial in HFpEF. PARAGON-HF (NCT 01920711) will utilize a similar overall study design to PARAMOUNT to determine whether LCZ can reduce cardiovascular death or total heart failure hospitalizations in patients with HFpEF. PARAGON-HF will enroll 4300 patients with HFpEF, LVEF >= 45%, history of heart failure hospitalization within 9 months or elevated natriuretic peptides, and evidence of structural heart disease, evidenced by left ventricular hypertrophy or left atrial enlargement. The primary endpoint for the trial will be a composite of cardiovascular death or total heart failure hospitalizations utilizing recurrent event methods.
Heart Failure with Reduced Ejection Fraction
The PARADIGM trial was designed to test the hypothesis that LCZ696 could result in reduced morbidity and mortality in patients with heart failure and reduced ejection fraction (LVEF <= 40%). Inclusion criteria included NYHA functional class II-IV, LVEF ≤40%, plasma BNP ≥150 pg/mL (or NT-proBNP ≥600 pg/mL), or a BNP ≥100 pg/mL (or NT-proBNP ≥400 pg/mL) if the patient was previously hospitalized for heart failure within the last 12 months.
Patients were required to be taking a stable dose of an ACE inhibitor or ARB equivalent to enalapril ≥10mg daily for at least 4 weeks prior to screening. Other inclusion criteria included eGFR ≥30 mL/min/1.73 m2, systolic BP ≥95 mmHg, and potassium ≤5.4 mmol/L. The primary endpoint was the composite of cardiovascular mortality or hospitalization for heart failure.
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Secondary endpoints included time to worsening of renal function and all-cause mortality.
PARADIGM employed a unique study design, with a single-blind active run-in period designed to ensure that patients tolerated both study drugs. Patients who completed run-in were randomly assigned to LCZ696 200mg bid or enalapril 10mg bid in a double-blind fashion (24) . The run-in period afforded the data safety monitoring board early information regarding measures of safety, including hypotension, renal function and hyperkalemia since prior experience with this drug in heart failure had been extremely limited. Enalapril 10mg bid was utilized as the active compared as this has been considered both standard of care and the regulatory gold standard in heart failure. A sample size of approximately 8000 patients was required to have 80% power to reduce cardiovascular death by 15%. This number of patients provided > 97% power to reduce the primary composite endpoint by 15%. By powering the study for cardiovascular death, it was overpowered for the primary endpoint.
Ultimately, 8442 patients were randomized from 947 sites in 47 countries (of these, 43
were removed from final analysis due to mis-randomization or major good clinical practice violations at the sites).(25) Baseline characteristics represented a typical HFrEF population, with a mean LVEF = 29 ± 6%, and optimized background therapy including beta blockers (93%) and mineralocorticoid receptor antagonists (60%). The study population was predominantly NYHA class II (70%) and class III (24%). Natriuretic peptides were elevated (NT-proBNP mean 1600 pg/ml; BNP mean 250 pg/ml).
In late March, 2014, the PARADIGM data monitoring committee (DMC) reviewed the interim safety and efficacy data and recommended early termination of the trial for efficacy, indicating a significant reduction in both the primary endpoint (cardiovascular death or heart failure hospitalization) and in cardiovascular death 
